iScience, Год журнала: 2024, Номер 27(8), С. 110524 - 110524
Опубликована: Июль 20, 2024
RNA methylation has emerged as a dynamic regulatory mechanism that impacts gene expression and protein synthesis. Among the known modifications, N6-methyladenosine (m
Язык: Английский
Journal of Orthopaedic Surgery and Research, Год журнала: 2023, Номер 18(1)
Опубликована: Сен. 18, 2023
Knee osteoarthritis (KOA) is characterized by joint wear and degeneration. Unfortunately, the medical community currently lacks effective treatment options for this disease. Suspension exercise therapy considered an form of non-weight-bearing treating KOA. However, its mechanism intervention in KOA unclear. Therefore, study aimed to evaluate protective effects on rats with attempted explore underlying mechanisms.In study, a papain-induced model was constructed, pathological changes cartilage tissue were observed hematoxylin eosin (H&E) staining scored according Mankin scoring principle. The serum levels interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α) detected enzyme-linked immunosorbent assay. Reverse transcription-quantitative polymerase chain reaction Western blotting used detect expression mRNA proteins TLR4/MyD88/NF-κB signaling pathway.H&E score data confirmed that significantly improved articular degradation compared group. Further, we differentially reduced IL-1β, TNF-α. Mechanistically, downregulated gene protein TLR4, MyD88, NF-κB tissue.Non-weight-bearing resulted progression modulating pathway decreasing inflammatory cytokines TNF-α slow down degeneration cartilage.
Язык: Английский
Процитировано
7
Cells, Год журнала: 2023, Номер 12(14), С. 1821 - 1821
Опубликована: Июль 11, 2023
Osteoarthritis (OA) is a joint disorder characterized by progressive degeneration of cartilage extracellular matrix (ECM), chondrocyte hypertrophy and apoptosis inflammation. The current treatments mainly concern pain control reduction inflammation, but no therapeutic strategy has been identified as disease-modifying treatment. Therefore, identifying specific biomarkers useful to prevent, treat or distinguish the stages OA disease become an immediate need clinical practice. role microRNAs (miRNAs) in investigated last decade, increasing evidence emerged that influence environment on gene expression through epigenetic processes contributes development, progression aggressiveness OA, particular acting microenvironment modulations. effects regulation, particularly different miRNA methylation during disease, were highlighted present systematic review. arising from this study literature conducted three databases (PubMed, Scopus, Web Science) suggested state already strongly impacts progression, driving chondrocytes synoviocyte proliferation, apoptosis, inflammation ECM deposition. However, possibility understanding mechanism which modifications pre-miRNA sequences drive could be new focus future investigations.
Язык: Английский
Процитировано
6
Pathology - Research and Practice, Год журнала: 2024, Номер 255, С. 155220 - 155220
Опубликована: Фев. 21, 2024
Язык: Английский
Процитировано
2
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Апрель 17, 2024
Background The efficacy and safety of different immunosuppressants combined with chemotherapy in treating patients small-cell lung cancer (extensive-disease cancer, limited-disease relapsed cancer) are still unknown, there no reports directly comparing the other immunotherapies. Objective This study aimed to compare first-line immunotherapy cancer. Method We searched Pubmed, Embase, Cochrane Library, CNKI, Wanfang databases for relevant articles published from inception November 11, 2020. risk bias included studies was conducted using risk-of-bias (RoB) tool. Multiple Bayesian network meta-analyses were performed. They data analysis R Studio STATA version 15.1. outcomes comprised overall survival (OS), progression-free (PFS), stability response (SOR), duration (DOR) adverse events grade 3 or higher (AE grade≥3). A 95% confidence interval (CI) provided each estimate. Results meta-analysis 16 RCT 5898 patients. For OS, relative (MD=-4.49; 95%CI [-7.97, -1.03]), durvalumab plus tremelimumab (MD=-4.62; [-9.08, -0.11]), ipilimumab (MD=-4.26; [-8.01, -0.3]) nivolumab(MD=-5.66; [-10.44, -1.11]) nivolumab (MD=-4.56; [-8.7, -0.1]), serplulimab can significantly increase OS SCLC There significant difference between PFS, SOR DOR. Analysis AE showed that regimens similar single regarding incidence grade≥3. However, after cumulative ranking common symptoms reactions, it found ranked first occurrence probability anemia (99.08%), fatigue (84.78%), decreased appetite (89.66%). most likely nausea (75.4%). Pembrolizumab (76.24%) cause pruritus. Chemotherapy caused less diarrhea than alone (80.16%). Conclusions According our analysis, is more show better a manageable profile evidence this comparison shows some limitations due number literature. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42023486053.
Язык: Английский
Процитировано
2
iScience, Год журнала: 2024, Номер 27(8), С. 110524 - 110524
Опубликована: Июль 20, 2024
RNA methylation has emerged as a dynamic regulatory mechanism that impacts gene expression and protein synthesis. Among the known modifications, N6-methyladenosine (m
Язык: Английский
Процитировано
2